EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims against Vitae Pharmaceuticals, Inc. – VTAE

The Rosen Law Firm, P.A., a global investor rights firm, announces it is investigating potential securities claims on behalf of shareholders of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) resulting from allegations that Vitae Pharmaceuticals may have issued materially misleading business information to the investing public.

On February 27, 2015, Vitae Pharmaceuticals announced that its partner Boehringer Ingelheim has voluntarily placed a temporary clinical hold on BI 1181181—an orally-active beta secretase (BACE) inhibitor being evaluated in Phase 1 clinical trials for the treatment and prevention of Alzheimer's disease—and has notified regulatory agencies of its decision. This temporary clinical hold was placed to further investigate skin reactions observed in some study participants during the multiple rising dose trial. On this news, shares of Vitae Pharmaceuticals fell sharply during intraday trading on February 27, 2015, damaging investors.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Vitae Pharmaceuticals investors. If you purchased shares of Vitae Pharmaceuticals before February 27, 2015, please visit the website at http://rosenlegal.com/cases-524.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.